RxDoctor Payments Data

Paul Linder, MD

Internal Medicine · West Mifflin, PANPI 1992709349

Payments from drug & device makers

$54,366in general payments, 2019–2025

Across 118 payments — averaging $460.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$52K
  • AstraZeneca$777
  • Novo Nordisk$383
  • Pfizer$287
  • Inari Medical, Inc.$189
  • AbbVie$185
  • plus $954 from 11 others

What the payments were for

  • Consulting fees$51,09294%
  • Travel & lodging$260%
  • Food & beverage$2,7745%
  • Education$4751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,366 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$53,207
Medicare patients
147
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$118,370
EliquisApixaban107$95,048
OzempicSemaglutide40$45,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$34,192
RybelsusSemaglutide35$31,479
XareltoRivaroxaban18$25,625
JanuviaSitagliptin Phosphate16$23,600
FarxigaDapagliflozin Propanediol23$22,046
TradjentaLinagliptin16$16,071
Breo ElliptaFluticasone/Vilanterol22$9,223
Novolog FlexpenInsulin Aspart17$5,502
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$5,167
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,480
Nano 2nd Gen Pen NeedlePen Needle, Diabetic46$3,164
Atorvastatin Calcium364$3,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$62$134,441133 claims
PfizerEliquis$287$95,048107 claims
Novo NordiskOzempic, Rybelsus$383$76,82675 claims
GSKTrelegy Ellipta, Breo Ellipta$82$43,41667 claims
Johnson & JohnsonXarelto$157$25,62518 claims
AstraZenecaFarxiga$777$22,04623 claims
AbbVieSynthroid$185$91421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in West Mifflin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →